Table 3.
High-throughput studies of mRNA expression.
| Studies | Ito et al. (45) | Snoeren et al. (46) | Snoeren et al. (49) | Balachandran et al. (48) | Van der Stok et al. (47) |
|---|---|---|---|---|---|
| Nr of patients | 96 | 119 | 30 | 96 test [Ito et al. (45)] | 63 |
| (only CRC stage II/III) | 119 validation [Snoeren et al. (42)] | ||||
| Experimental methods | Illumina, HumanHT-12 Gene Chip v3.0 Expression Beadchip | Qiagen, Human Array-Ready Oligo set (version 2.0) | Qiagen, Human Array-Ready Oligo set (version 2.0) | See Ito et al. (45) and Snoeren (46) | Illumina, HumanHT-12 v4 Expression BeadChip |
| Statistics | Supervised principle component method | Multivariate cox regression | MAANOVA | Multivariate cox regression | Leave one out cross validation |
| Neoadjuvant chemo | 72% | In DFS ≤ 1 year: 62.5% | In DFS < 6 months: 29.4% | See Ito et al. (45) and Snoeren (46) | In DFS ≤ 1 year: 0% |
| In DFS > 1 year: 40.4% | In DFS > 24 months: 15.4% | In DFS > 3 year: 0% | |||
| Adjuvant chemo | 82% | In DFS ≤ 1 year: 45.8% | In DFS < 6 months: 94.1% | See Ito et al. (45) and Snoeren (46) | In DFS ≤ 1 year: 0% |
| In DFS > 1 year: 74.5% | In DFS > 24 months: 53.8% | In DFS > 3 year: 0% | |||
| Genes present in | BAG3 | BAT2 | AMPD1 | CES2 | CASS4 |
| signature | C1ORF218 | C6orf141 | ARL6IP5 | DKK1 | CLRN3 |
| C1ORF71 | CCDC85A | ASAP2 | DNAJC12 | COX6A1 | |
| CDC2L5 | CPLX1 | BNIP3 | FGFBP1 | ERN1 | |
| CHN2 | FAM174B | C13orf3 | HOXC6 | G3BP2 | |
| CKS2 | FRMD6 | COLEC11 | LRP8 | ITGB5 | |
| FGFBP1 | GPR143 | FYTTD1 | LRRC42 | JARID1A | |
| FLJ39632 | hsa-mir-103-2 | GDF15 | NUP62CL | KIAA0319 | |
| HSGT1 | ITSN1 | GTF3C3 | ODC1 | RAD9A | |
| LRRC42 | KIAA0562 | LAPTM4A | PLA2G2A | RPUSD1 | |
| PCBD1 | MAPKAPK2 | LYPLAL1 | PLCB4 | ULBP2 | |
| PLCB4 | MYNN | SERPINB5 | RAD23B | ||
| RAD23B | OR5P2 | SMYD2 | RBBP8 | ||
| RNF135 | OTUD5 | THEM2 | REG4 | ||
| RPS24 | PARN | RNF135 | |||
| SLC28A3 | RIPK4 | RPS24 | |||
| TIMM23 | RP11-347C12.2 | SERPINB1 | |||
| ZNF827 | ZNF134 | SMIM24 | |||
| chrX:142692034-142692102 | STEAP1 TS | ||||
Five studies report on high-throughput mRNA expression. We report on the number of patients, the experimental method and protocol, and the statistical method. Furthermore, we report the percentage of patients in the different experimental patient groups that received neoadjuvant and/or adjuvant chemotherapy. Finally, we show the presented gene signatures that predict patient survival in these four different studies. Genes related to the immune system are in bold and italics.